A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastin Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer

Trial Profile

A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastin Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms INVICTAN-2
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 18 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 06 Jul 2015 Planned End Date changed from 1 Apr 2019 to 1 Mar 2019 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top